Clinical Trials · NCT05555589
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- ReGenTree, LLC
- Enrollment
- 70
- Start date
- Apr 2023
- Locations
- 36 sites, 4 countries
- Primary endpoint
- Percentage of subjects achieving complete healing of PED at Day 29